A Look at Collegium Pharmaceutical’s (COLL) Valuation After Upbeat Q3 Results and Raised Guidance

Collegium Pharmaceutical (COLL) shares got a nice lift after the company topped expectations in its third-quarter results. Revenue and earnings both saw strong year-over-year gains, and management raised their outlook for the full year.

See our latest analysis for Collegium Pharmaceutical.

Collegium Pharmaceutical’s share price has rallied sharply on the back of its upbeat quarterly results and improved full-year outlook, jumping more than 27% over the last month and delivering a standout 48% year-to-date share price return. That recent momentum builds on a multi-year stretch of strong performance, with total shareholder returns topping 31% over the past year and more than doubling over the last three years. These results are clear signals that investors are increasingly optimistic about the company’s growth potential following strategic moves such as the Jornay PM acquisition.

If you’re interested in discovering other compelling companies in healthcare and biotech, check out See the full list for free..

With shares soaring and guidance now higher, the key question is whether Collegium Pharmaceutical remains undervalued or if the market has already priced in the company’s recent success. This could potentially leave limited room for further upside.

Compared to the last close of $42.30, the most popular narrative estimates Collegium Pharmaceutical’s fair value at $46.80, reflecting a meaningful upside that still factors in recent performance upgrades. This narrative leans on stronger profit margin assumptions and resilience from a diversified portfolio, setting the foundation for a bullish outlook.

Collegium’s disciplined capital allocation and ongoing business development (M&A) strategy, including pursuing synergistic pain/CNS assets, is expected to drive portfolio diversification and inorganic growth. This further reduces revenue concentration risk and provides additional sources of EBITDA and earnings stability.

Read the complete narrative.

What is powering this premium? The full narrative reveals bold expectations for profit margins, earnings growth, and a cut in the company’s future trading multiple. Eager to see which figures have analysts forecasting continued upside? Dive into the details fueling this confidence.

Result: Fair Value of $46.80 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, ongoing regulatory scrutiny and potential generic competition for key pain products could put pressure on Collegium’s revenue and margin outlook in the years ahead.

Find out about the key risks to this Collegium Pharmaceutical narrative.

While the narrative-driven approach suggests Collegium Pharmaceutical is undervalued, a glance at its price-to-earnings ratio tells a more cautious story. Shares are trading at 22.9 times earnings, above both the US Pharmaceuticals industry average of 17.9x and the peer group’s 22.3x. The fair ratio, which is the level the market could revert toward, is estimated at 16.6x. This indicates that the current price is stretched in valuation terms. Evidence of this kind of gap often signals heightened risk for investors if the business does not deliver on high expectations.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:COLL PE Ratio as at Nov 2025

If you have different assumptions or want to dig into the numbers yourself, try building your own narrative in just a few minutes and see where it leads: Do it your way.

A great starting point for your Collegium Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Smart investors stay ahead of the curve. Secure your edge by checking out cutting-edge opportunities using the tailored screeners below. Why settle for ordinary when you can aim higher?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include COLL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

No Byline Policy

Editorial Guidelines

Corrections Policy

Source